Brentuximab Vedotin plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Estado	**Tipo de Participantes**	**Rangos de Edad**
EC Finalizado	No aportado	Mayores de 64 , Adultos (18-64 años)
Género	**Fases**	**Participantes esperados**
Ambos	Fase III	134
Resultados	**Bajo nivel intervención**	**Enfermedad rara**
Sin resultados	No	No
Cobertura geográfica	**Ámbitos del ensayo**	**Terapia avanzada**
Sin determinar	tratamiento, seguridad, eficacia	NO

Información

Identificador

2023-503384-41-00 (CTIS)

Cod. Protocolo

SGN35-031

Transicionado 2020-002686-33

Área terapéutica

·Enfermedades [C] - Tracto respiratorio [C08]
·Procesos fisiológicos [G] - Fisiología de la circulación y de la respiración [G09]

Enfermedad investigada

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Título Científico

C5691003_A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

ECHELON-3

Justificación

No aportado

Objetivo Principal

Evaluate and compare overall survival (OS) between the 2 treatment arms in the intent-to-treat (ITT) population.

Variables de Evaluación Primaria

OS (Overall Survival)

Momentos temporales de evaluación primaria

No aportado

Objetivo Secundario

1.Evaluate and compare progression-free survival (PFS) per Lugano 2014 by investigator between the 2 treatment arms in the ITT population
2. Evaluate and compare the objective response rate (ORR) per Lugano 2014 by investigator between the 2 treatment arms in the ITT population

Variables de Evaluación Secundaria

PFS (progression-free survival) per Lugano 2014 by investigator
CR (complete response) rate per Lugano 2014 by investigator
DOR (duration of response) per Lugano 2014 by investigator
Incidence, severity, and seriousness of adverse events (AEs) per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0
OS in CD30-positive participants
ORR (objective response rate) per Lugano 2014 by investigator

Momentos temporales de evaluación secundaria

No aportado

Criterios de Inclusión

Participants with relapsed or refractory diffuse and transformed large B-cell lymphoma (R/R DLBCL). DLBCL and cell of origin (GCB versus non-GCB) will be histologically determined by the most recent local pathology assessment for the purposes of study eligibility and stratification. The following subtypes of DLBCL are eligible for enrollment: a. Not otherwise specified (NOS) b. Intravascular large B-cell lymphoma c. DLBCL associated with chronic inflammation d. EBV-positive NOS e. ALK-positive f. T-cell-/histiocyte-rich large B-cell lymphoma g. Primary mediastinal large B-cell lymphoma h. High-grade B-cell lymphoma with translocations of MYC and BCL2 and/or BCL6 (double-/triple-hit lymphoma) i. High-grade NOS B-cell lymphomas j. Primary cutaneous DLBCL (leg type) k. DLBCL arising from transformed indolent lymphomas/leukemias Participants who can father children, under the following conditions: a. Must agree not to donate sperm starting at time of informed consent and continuing throughout the study period and for at least 12 months after the final dose of study drug. b. If sexually active with a person of childbearing potential in a way that could lead to pregnancy, must consistently use 2 methods of birth control (see Appendix C) starting at time of informed consent and continuing throughout the study and for at least 12 months after the final dose of study drug. c. If sexually active with a person who is pregnant or breastfeeding, must consistently use one of the contraception options (see Appendix C) starting at time of informed consent and continuing throughout the study and for at least 12 months after the final dose of study drug The following requirements for participants who are known to be human immunodeficiency virus (HIV) positive: CD4+ T-cell counts 350 cells/mm3 within 28 days of Day 1 No acquired immune deficiency syndrome-defining opportunistic infection within the past 12 months On established highly active antiretroviral therapy for at least 4 weeks with an HIV viral load less than 400 copies/mL within 28 days of Day 1 (see Section 5.6.2 for participants receiving strong CYP3A inhibitors). The subject must provide written informed consent Participants must have R/R disease following 2 lines of prior systemic therapy. For participants with transformed DLBCL (subtype k), at least the last systemic therapy used must have been for DLBCL. Participants must be HSCT or CAR-T ineligible according to the investigator and must meet at least one of the following criteria: a. One or more co-morbidities, including cardiac, pulmonary, renal or hepatic dysfunction that in the opinion of the Investigator make the subject medically unfit to receive HSCT or CAR-T therapy. b. Active disease following induction and salvage chemotherapy c. Inadequate stem cell mobilization (for HSCT) d. Relapse following prior HSCT or CAR-T e. Unable to receive CAR-T therapy due to financial, geographic, insurance, or manufacturing issues. Participants must have tumor tissue submitted to the central pathology lab for the determination of CD30 expression, which will be centrally determined by visual assessment for any detectable level of CD30 on tumor cells by IHC. The most recent biopsy available that contains viable DLBCL tissue should be submitted. If the CD30 results from the central pathology lab are not available prior to randomization, the subject may be stratified based on % CD30 expression from the local pathology lab. Participants who are stratified based on local pathology lab results must have the same archived tumor tissue sent in for central CD30 evaluation within 2 weeks of enrollment. Age 18 and older An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2 Participants must have fluorodeoxyglucose (FDG)-avid disease by positron emission tomography (PET) and bidimensional measurable disease of > 1.5 cm by computed tomography (CT), as assessed by the site radiologist within 28 days of Day 1. a. PET and CT imaging performed prior to consent but within 28 days of Day 1 can be used The following baseline laboratory data within 28 days of Day 1: a. Absolute neutrophil count (ANC) 1000/L. If recent G-CSF has been used, the ANC result must be 14 days after last dose of pegylated G-CSF or 7 days after last dose of G-CSF. b. Platelet count 50,000/L at least 7 days after last treatment for DLBCL with no platelet transfusion during this 7-day period. c. For participants whose last therapy was CAR-T therapy, the ANC and platelet count requirements must be met at least twice during screening, with the measurements at least 7 days apart. d. Hemoglobin 8.0 g/dL and have not received a transfusion in the 7 days prior to testing e. Serum bilirubin 1.5 x upper limit of normal (ULN) or 3 x ULN for participants with Gilberts disease or documented hepatic involvement with lymphoma. f. Estimated glomerular filtration rate (eGFR) 45 mL/min using the Cockcroft-Gault (C-G) formula, with serum creatinine (Scr) reported in mg/dL. o eGFR (mL/min) = ([140 age] x weight [kg] x 0.85 [if female]) / (Scr x 72) g. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 3.0 x ULN or 5.0 x ULN for participants with documented hepatic involvement with lymphoma. h. Labs performed prior to consent but within 28 days of Day 1 can be used. Participants of childbearing potential, as defined in Section 4.3, under the following conditions. a. Must avoid pregnancy for at least 4 weeks before beginning lenalidomide therapy, during therapy, during dose interruptions, and for at least 12 months after completing therapy. Participants must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of birth control simultaneously: one highly effective form of contraception tubal ligation, intrauterine device (IUD), hormonal (birth control pills, injections, hormonal patches, vaginal rings, or implants), or partners vasectomy, and 1 additional effective contraceptive method male latex or synthetic condom,

diaphragm, or cervical cap (see Appendix C), beginning 4 weeks prior to initiating treatment with lenalidomide, during therapy, during dose interruptions, and continuing for 12 months following discontinuation of study drug (brentuximab vedotin, rituximab, or lenalidomide). Two negative beta human chorionic gonadotropin (-HCG) pregnancy tests must be obtained prior to initiating therapy. The first test must be a serum -HCG pregnancy test and the second test can either be a serum or urine -HCG pregnancy test. The first test should be performed within 10 to 14 days and the second test performed within 24 hours prior to receiving lenalidomide therapy. Afterwards, a serum -HCG pregnancy test must be administered weekly during the first month, then at least monthly thereafter in females with regular menstrual cycles or every 2 weeks in participants with irregular menstrual cycles. b. Must agree not to try to become pregnant during the study and for at least 12 months after the final dose of study drug. c. Must agree not to breastfeed or donate ova, starting at time of informed consent and continuing through 12 months after the final dose of study drug. d. If sexually active in a way that could lead to pregnancy, must consistently use 2 methods of birth control as described in Inclusion criterion 9a, starting at time of informed consent and continuing throughout the study and for at least 12 months after the final dose of study drug

Criterios de Exclusión

History of another malignancy within 2 years before the first dose of study drug or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death (eg, 5-year OS 90%), such as carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer Participants with previous allogeneic HSCT if they meet either of the following criteria: <100 days from HSCT Active acute or chronic graft-versus-host disease (GVHD) or receiving immunosuppressive therapy as treatment for or prophylaxis against GVHD Previous treatment with brentuximab vedotin or lenalidomide. a. Previous treatment with other vedotin-based ADCs is permitted if the last dose is at least 6 months prior to Day 1 Current therapy with immunosuppressive medications (including steroids), other systemic anti-neoplastic, or investigational agents. a. Prednisone (or equivalent) 10 mg/day may be used for non-lymphomatous purposes Documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, pulmonary embolism, or cardiac symptoms consistent with New York Heart Association (NYHA) Class III-IV within 6 months prior to the first dose of study drugs Congestive heart failure, Class III or IV, by the NYHA criteria (see Appendix D). Grade 2 or higher peripheral sensory or motor neuropathy at baseline Other serious underlying medical condition that, in the opinion of the investigator, would impair the subjects ability to receive or tolerate the planned treatment, and complete study assessments History of progressive multifocal leukoencephalopathy (PML). Active cerebral/meningeal disease related to the underlying malignancy. Participants with a history of cerebral/meningeal disease related to the underlying malignancy are allowed if prior CNS disease has been effectively treated and without progression for at least 3 months Any uncontrolled Grade 3 or higher (per NCI CTCAE version 5.0) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study drug. Routine antimicrobial prophylaxis is permitted Chemotherapy, radiotherapy, biologics, and/or other antitumor treatment with immunotherapy that is not completed 3 weeks prior to first dose of study drug, unless underlying disease has progressed on treatment Participants who are breastfeeding Known hypersensitivity to any study drug or excipient contained in the drug formulation of the study drugs Any contraindication to associated study treatments Known to be positive for hepatitis B by surface antigen expression. Participants who are hepatitis B surface antigen (HBsAg) negative but hepatitis B core antibody (HBcAb) positive are eligible, but should start hepatitis B prophylaxis therapy prior to receiving the first dose of rituximab. Known to be positive for hepatitis C (HCV) infection (either confirmed positive by polymerase chain reaction [PCR] or on antiviral therapy for hepatitis C within the last 6 months). Participants who have been treated for hepatitis C infection are permitted if they have documented sustained virologic response of 12 weeks

Calendario

(Última actualización: 11/06/2026)

Autorización	Inicio de Ensayo	Inclusión Primer Paciente	Interrumpido	Reiniciado
21/01/2021	25/03/2021	16/06/2021	No aportado	No aportado

Fin de reclutamiento	Fin prematuro (España)	Fin prematuro (Global)	Fin del ensayo en España	Fin del ensayo global
23/11/2023	No aportado	No aportado	12/03/2026	No aportado

Promotor

Seagen Inc. United States

21823 30th Drive Southeast

Contact Person

Clinical Medical Lead

+18007181021

ClinicalTrials.gov@pfizer.com

Monetary support: N/A

Tipo de promotor: Comercial

Ceim

CEIm Hospital Universitario 12 de Octubre

Glorieta de Málaga, S/N 28041 Madrid

ceic@h12o.es

917792613

Centros

Cerrado (09/08/2024)

CLINICA UNIVERSIDAD DE NAVARRA

Pamplona/Iruña

NAVARRA

Cerrado (21/06/2023)

Complejo Hospitalario Infanta Leonor

Madrid

MADRID

Cerrado (07/08/2025)

HOSPITAL CLINICO UNIVERSITARIO DE SALAMANCA (COMPLEJO ASISTENCIAL UNIV.SA)

Salamanca

SALAMANCA

Cerrado (02/09/2025)

HOSPITAL COSTA DEL SOL

Marbella

MÁLAGA

Cerrado (08/04/2026)

HOSPITAL DE LA SANTA CREU I SANT PAU

Barcelona

BARCELONA

Cerrado (08/04/2026)

Hospital De La Santa Creu I Sant Pau

Barcelona

BARCELONA

AGDAC

Cerrado (05/11/2025)

Hospital Del Mar

Barcelona

BARCELONA

Hematology department

Cerrado (08/04/2026)

HOSPITAL SAN PEDRO DE ALCANTARA

Cáceres

CÁCERES

Cerrado (12/01/2024)

HOSPITAL UNIVERSITARI VALL D'HEBRON

Barcelona

BARCELONA

Cerrado (30/11/2023)

HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS

Oviedo

ASTURIAS

Cerrado (18/01/2024)

HOSPITAL UNIVERSITARIO DE NAVARRA

Pamplona/Iruña

NAVARRA

Cerrado (03/09/2025)

HOSPITAL UNIVERSITARIO FUNDACION JIMENEZ DIAZ

Madrid

MADRID

Cerrado (04/09/2025)

HOSPITAL UNIVERSITARIO LA PAZ

Madrid

MADRID

Cerrado (09/02/2024)

HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA

Majadahonda

MADRID

Cerrado (01/09/2025)

HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID

Pozuelo de Alarcón

MADRID

Cerrado (27/06/2023)

Hospital Universitario Regional De Malaga

Málaga

MÁLAGA

Cerrado (05/10/2022)

Hospital Universitario Virgen Del Rocio

Sevilla

SEVILLA

Cerrado (06/02/2024)

HOSPITAL UNIVERSITARIO 12 DE OCTUBRE

Madrid

MADRID

Cerrado (06/02/2024)

Hospital Universitario 12 De Octubre

Madrid

MADRID

Medical Oncology Department

Cerrado (04/06/2025)

Institut Catala D'oncologia

Hospitalet de Llobregat, L'

BARCELONA

Cerrado (05/09/2024)

Institut Catala D'oncologia

Badalona

BARCELONA

Medicamentos

-

-

SUBCUTANEOUS INJECTION

Código ATC: L01XC02 - RITUXIMAB

Principios Activos: N/A

Experimental

Revlimid 5 mg hard capsules

CAPSULE, HARD

ORAL

Código ATC: L04AX04 - LENALIDOMIDA

Principios Activos: N/A

Huérfano

Experimental

BRENTUXIMAB VEDOTIN

POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION

SUBCUTANEOUS INJECTION

-

Principios Activos: N/A

Experimental

Sin resultados

Brentuximab Vedotin plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

State	**Type of participants**	**Age Ranges**
Finished CT	Not provided	Older than 64 , Adults (18-64 years)
Gender	**Phases**	**Expected Participants**
Both	Phase III	134
Results	**Low level of intervention**	**Rare disease**
No results	No	No
Geographic coverage	**Areas of the study**	**Advanced therapy**
Undetermined	treatment, safety, effectiveness	NO

Information

Identifier

2023-503384-41-00 (CTIS)

Protocol Code

SGN35-031

Transitioned 2020-002686-33

Therapeutic area

·Diseases [C] - Respiratory Tract Diseases [C08]
·Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09]

Investigated Disease

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Scientific Title

C5691003_A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

ECHELON-3

Rationale

Not provided

Main Objective

Evaluate and compare overall survival (OS) between the 2 treatment arms in the intent-to-treat (ITT) population.

Primary Endpoints

OS (Overall Survival)

Temporary moments of secondary assessment

Not provided

Secondary Objective

1.Evaluate and compare progression-free survival (PFS) per Lugano 2014 by investigator between the 2 treatment arms in the ITT population
2. Evaluate and compare the objective response rate (ORR) per Lugano 2014 by investigator between the 2 treatment arms in the ITT population

Secondary Endpoints

PFS (progression-free survival) per Lugano 2014 by investigator
CR (complete response) rate per Lugano 2014 by investigator
DOR (duration of response) per Lugano 2014 by investigator
Incidence, severity, and seriousness of adverse events (AEs) per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0
OS in CD30-positive participants
ORR (objective response rate) per Lugano 2014 by investigator

Temporary moments of secondary assessment

Not provided

Inclusion criteria

Participants with relapsed or refractory diffuse and transformed large B-cell lymphoma (R/R DLBCL). DLBCL and cell of origin (GCB versus non-GCB) will be histologically determined by the most recent local pathology assessment for the purposes of study eligibility and stratification. The following subtypes of DLBCL are eligible for enrollment: a. Not otherwise specified (NOS) b. Intravascular large B-cell lymphoma c. DLBCL associated with chronic inflammation d. EBV-positive NOS e. ALK-positive f. T-cell-/histiocyte-rich large B-cell lymphoma g. Primary mediastinal large B-cell lymphoma h. High-grade B-cell lymphoma with translocations of MYC and BCL2 and/or BCL6 (double-/triple-hit lymphoma) i. High-grade NOS B-cell lymphomas j. Primary cutaneous DLBCL (leg type) k. DLBCL arising from transformed indolent lymphomas/leukemias Participants who can father children, under the following conditions: a. Must agree not to donate sperm starting at time of informed consent and continuing throughout the study period and for at least 12 months after the final dose of study drug. b. If sexually active with a person of childbearing potential in a way that could lead to pregnancy, must consistently use 2 methods of birth control (see Appendix C) starting at time of informed consent and continuing throughout the study and for at least 12 months after the final dose of study drug. c. If sexually active with a person who is pregnant or breastfeeding, must consistently use one of the contraception options (see Appendix C) starting at time of informed consent and continuing throughout the study and for at least 12 months after the final dose of study drug The following requirements for participants who are known to be human immunodeficiency virus (HIV) positive: CD4+ T-cell counts 350 cells/mm3 within 28 days of Day 1 No acquired immune deficiency syndrome-defining opportunistic infection within the past 12 months On established highly active antiretroviral therapy for at least 4 weeks with an HIV viral load less than 400 copies/mL within 28 days of Day 1 (see Section 5.6.2 for participants receiving strong CYP3A inhibitors). The subject must provide written informed consent Participants must have R/R disease following 2 lines of prior systemic therapy. For participants with transformed DLBCL (subtype k), at least the last systemic therapy used must have been for DLBCL. Participants must be HSCT or CAR-T ineligible according to the investigator and must meet at least one of the following criteria: a. One or more co-morbidities, including cardiac, pulmonary, renal or hepatic dysfunction that in the opinion of the Investigator make the subject medically unfit to receive HSCT or CAR-T therapy. b. Active disease following induction and salvage chemotherapy c. Inadequate stem cell mobilization (for HSCT) d. Relapse following prior HSCT or CAR-T e. Unable to receive CAR-T therapy due to financial, geographic, insurance, or manufacturing issues. Participants must have tumor tissue submitted to the central pathology lab for the determination of CD30 expression, which will be centrally determined by visual assessment for any detectable level of CD30 on tumor cells by IHC. The most recent biopsy available that contains viable DLBCL tissue should be submitted. If the CD30 results from the central pathology lab are not available prior to randomization, the subject may be stratified based on % CD30 expression from the local pathology lab. Participants who are stratified based on local pathology lab results must have the same archived tumor tissue sent in for central CD30 evaluation within 2 weeks of enrollment. Age 18 and older An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2 Participants must have fluorodeoxyglucose (FDG)-avid disease by positron emission tomography (PET) and bidimensional measurable disease of > 1.5 cm by computed tomography (CT), as assessed by the site radiologist within 28 days of Day 1. a. PET and CT imaging performed prior to consent but within 28 days of Day 1 can be used The following baseline laboratory data within 28 days of Day 1: a. Absolute neutrophil count (ANC) 1000/L. If recent G-CSF has been used, the ANC result must be 14 days after last dose of pegylated G-CSF or 7 days after last dose of G-CSF. b. Platelet count 50,000/L at least 7 days after last treatment for DLBCL with no platelet transfusion during this 7-day period. c. For participants whose last therapy was CAR-T therapy, the ANC and platelet count requirements must be met at least twice during screening, with the measurements at least 7 days apart. d. Hemoglobin 8.0 g/dL and have not received a transfusion in the 7 days prior to testing e. Serum bilirubin 1.5 x upper limit of normal (ULN) or 3 x ULN for participants with Gilberts disease or documented hepatic involvement with lymphoma. f. Estimated glomerular filtration rate (eGFR) 45 mL/min using the Cockcroft-Gault (C-G) formula, with serum creatinine (Scr) reported in mg/dL. o eGFR (mL/min) = ([140 age] x weight [kg] x 0.85 [if female]) / (Scr x 72) g. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 3.0 x ULN or 5.0 x ULN for participants with documented hepatic involvement with lymphoma. h. Labs performed prior to consent but within 28 days of Day 1 can be used. Participants of childbearing potential, as defined in Section 4.3, under the following conditions. a. Must avoid pregnancy for at least 4 weeks before beginning lenalidomide therapy, during therapy, during dose interruptions, and for at least 12 months after completing therapy. Participants must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of birth control simultaneously: one highly effective form of contraception tubal ligation, intrauterine device (IUD), hormonal (birth control pills, injections, hormonal patches, vaginal rings, or implants), or partners vasectomy, and 1 additional effective contraceptive method male latex or synthetic condom,

diaphragm, or cervical cap (see Appendix C), beginning 4 weeks prior to initiating treatment with lenalidomide, during therapy, during dose interruptions, and continuing for 12 months following discontinuation of study drug (brentuximab vedotin, rituximab, or lenalidomide). Two negative beta human chorionic gonadotropin (-HCG) pregnancy tests must be obtained prior to initiating therapy. The first test must be a serum -HCG pregnancy test and the second test can either be a serum or urine -HCG pregnancy test. The first test should be performed within 10 to 14 days and the second test performed within 24 hours prior to receiving lenalidomide therapy. Afterwards, a serum -HCG pregnancy test must be administered weekly during the first month, then at least monthly thereafter in females with regular menstrual cycles or every 2 weeks in participants with irregular menstrual cycles. b. Must agree not to try to become pregnant during the study and for at least 12 months after the final dose of study drug. c. Must agree not to breastfeed or donate ova, starting at time of informed consent and continuing through 12 months after the final dose of study drug. d. If sexually active in a way that could lead to pregnancy, must consistently use 2 methods of birth control as described in Inclusion criterion 9a, starting at time of informed consent and continuing throughout the study and for at least 12 months after the final dose of study drug

Exclusion criteria

History of another malignancy within 2 years before the first dose of study drug or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death (eg, 5-year OS 90%), such as carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer Participants with previous allogeneic HSCT if they meet either of the following criteria: <100 days from HSCT Active acute or chronic graft-versus-host disease (GVHD) or receiving immunosuppressive therapy as treatment for or prophylaxis against GVHD Previous treatment with brentuximab vedotin or lenalidomide. a. Previous treatment with other vedotin-based ADCs is permitted if the last dose is at least 6 months prior to Day 1 Current therapy with immunosuppressive medications (including steroids), other systemic anti-neoplastic, or investigational agents. a. Prednisone (or equivalent) 10 mg/day may be used for non-lymphomatous purposes Documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, pulmonary embolism, or cardiac symptoms consistent with New York Heart Association (NYHA) Class III-IV within 6 months prior to the first dose of study drugs Congestive heart failure, Class III or IV, by the NYHA criteria (see Appendix D). Grade 2 or higher peripheral sensory or motor neuropathy at baseline Other serious underlying medical condition that, in the opinion of the investigator, would impair the subjects ability to receive or tolerate the planned treatment, and complete study assessments History of progressive multifocal leukoencephalopathy (PML). Active cerebral/meningeal disease related to the underlying malignancy. Participants with a history of cerebral/meningeal disease related to the underlying malignancy are allowed if prior CNS disease has been effectively treated and without progression for at least 3 months Any uncontrolled Grade 3 or higher (per NCI CTCAE version 5.0) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study drug. Routine antimicrobial prophylaxis is permitted Chemotherapy, radiotherapy, biologics, and/or other antitumor treatment with immunotherapy that is not completed 3 weeks prior to first dose of study drug, unless underlying disease has progressed on treatment Participants who are breastfeeding Known hypersensitivity to any study drug or excipient contained in the drug formulation of the study drugs Any contraindication to associated study treatments Known to be positive for hepatitis B by surface antigen expression. Participants who are hepatitis B surface antigen (HBsAg) negative but hepatitis B core antibody (HBcAb) positive are eligible, but should start hepatitis B prophylaxis therapy prior to receiving the first dose of rituximab. Known to be positive for hepatitis C (HCV) infection (either confirmed positive by polymerase chain reaction [PCR] or on antiviral therapy for hepatitis C within the last 6 months). Participants who have been treated for hepatitis C infection are permitted if they have documented sustained virologic response of 12 weeks

Calendar

(Last Update: 11/06/2026)

Authorization	Start of Trial	First patient inclusion	Halted	Restarted
21/01/2021	25/03/2021	16/06/2021	Not aported	Not aported

End of recruitment	Premature end (Spain)	Premature End (Global)	Trial end (Spain)	Trial end (Global)
23/11/2023	Not aported	Not aported	12/03/2026	Not aported

Sponsor

Seagen Inc. United States

21823 30th Drive Southeast

Contact Person

Clinical Medical Lead

+18007181021

ClinicalTrials.gov@pfizer.com

Monetary support: N/A

Sponsor type: Commercial

Ceim

CEIm Hospital Universitario 12 de Octubre

Glorieta de Málaga, S/N 28041 Madrid

ceic@h12o.es

917792613

Sites

Closed (09/08/2024)

CLINICA UNIVERSIDAD DE NAVARRA

Pamplona/Iruña

NAVARRA

Closed (21/06/2023)

Complejo Hospitalario Infanta Leonor

Madrid

MADRID

Closed (07/08/2025)

HOSPITAL CLINICO UNIVERSITARIO DE SALAMANCA (COMPLEJO ASISTENCIAL UNIV.SA)

Salamanca

SALAMANCA

Closed (02/09/2025)

HOSPITAL COSTA DEL SOL

Marbella

MÁLAGA

Closed (08/04/2026)

HOSPITAL DE LA SANTA CREU I SANT PAU

Barcelona

BARCELONA

Closed (08/04/2026)

Hospital De La Santa Creu I Sant Pau

Barcelona

BARCELONA

AGDAC

Closed (05/11/2025)

Hospital Del Mar

Barcelona

BARCELONA

Hematology department

Closed (08/04/2026)

HOSPITAL SAN PEDRO DE ALCANTARA

Cáceres

CÁCERES

Closed (12/01/2024)

HOSPITAL UNIVERSITARI VALL D'HEBRON

Barcelona

BARCELONA

Closed (30/11/2023)

HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS

Oviedo

ASTURIAS

Closed (18/01/2024)

HOSPITAL UNIVERSITARIO DE NAVARRA

Pamplona/Iruña

NAVARRA

Closed (03/09/2025)

HOSPITAL UNIVERSITARIO FUNDACION JIMENEZ DIAZ

Madrid

MADRID

Closed (04/09/2025)

HOSPITAL UNIVERSITARIO LA PAZ

Madrid

MADRID

Closed (09/02/2024)

HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA

Majadahonda

MADRID

Closed (01/09/2025)

HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID

Pozuelo de Alarcón

MADRID

Closed (27/06/2023)

Hospital Universitario Regional De Malaga

Málaga

MÁLAGA

Closed (05/10/2022)

Hospital Universitario Virgen Del Rocio

Sevilla

SEVILLA

Closed (06/02/2024)

HOSPITAL UNIVERSITARIO 12 DE OCTUBRE

Madrid

MADRID

Closed (06/02/2024)

Hospital Universitario 12 De Octubre

Madrid

MADRID

Medical Oncology Department

Closed (04/06/2025)

Institut Catala D'oncologia

Hospitalet de Llobregat, L'

BARCELONA

Closed (05/09/2024)

Institut Catala D'oncologia

Badalona

BARCELONA

Medication

-

-

SUBCUTANEOUS INJECTION

ATC code: L01XC02 - RITUXIMAB

Active Principles: N/A

Experimental

Revlimid 5 mg hard capsules

CAPSULE, HARD

ORAL

ATC code: L04AX04 - LENALIDOMIDA

Active Principles: N/A

Orphan

Experimental

BRENTUXIMAB VEDOTIN

POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION

SUBCUTANEOUS INJECTION

-

Active Principles: N/A

Experimental

No results